Diabetes mellitus induces Alzheimer’s disease pathology: Histopathological evidence from animal models

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Kimura, Nobuyuki ^a  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer s disease; Animal model; Diabetes mellitus; Insulin resistance; Pathology

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; TAU PROTEIN; INSULIN;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE MUTATION; HISTOPATHOLOGY; INSULIN RESISTANCE; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; ANIMAL; COMPLICATION; DISEASE MODEL; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INSULIN; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84962652102     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040503     Document Type: Review

References (131)

1. Selkoe, D.J. The molecular pathology of Alzheimer’s disease. Neuron 1991, 6, 487-498. [CrossRef]
2. Mattson, M.P. Pathway towards and away from Alzheimer’s disease. Nature 2004, 430, 631-639. [CrossRef] [PubMed]
3. Armstrong, R.A. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol. 2009, 47, 289-299. [PubMed]
4. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356. [CrossRef] [PubMed]
5. Cross, D.; Vial, C.; Maccioni, R.B. A tau-like protein interacts with stress fibers and microtubules in human and rodent cultured cell lines. J. Cell Sci. 1993, 105, 51-60. [PubMed]
6. Kosik, K.S.; Joachim, C.L.; Selkoe, D.J. Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer disease. PNAS 1986, 83, 4044-4048. [CrossRef] [PubMed]
7. Maccioni, R.B.; Cambiazo, V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol. Rev. 1995, 75, 835-864. [PubMed]
8. Mandelkow, E.M.; Biernat, J.; Drewes, G.; Gustke, N.; Trinczek, B.; Mandelkow, E. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol. Aging 1995, 16, 355-363. [CrossRef]
9. Kraegen, E.W.; Clark, P.W.; Jenkins, A.B.; Daley, E.A.; Chisholm, D.J.; Storlien, L.H. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991, 40, 1397-1403. [CrossRef] [PubMed]
10. Lind, L.; Lithell, H. Hypertension, hyperlipidemia, insulin resistance and obesity: Parts of a metabolic syndrome. Blood Press. Suppl. 1992, 4, 49-54. [PubMed]
11. Meigs, J.B. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrom? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am. J. Epidemiol. 2000, 152, 908-911. [CrossRef] [PubMed]
12. Leibson, C.L.; Rocca, W.A.; Hanson, V.A.; Cha, R.; Kokmen, E.; O’Brien, P.C.; Palumbo, P.J. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am. J. Epidemiol. 1997, 145, 301-308. [CrossRef] [PubMed]
13. Arvanitakis, Z.; Wilson, R.S.; Bienias, J.L.; Evans, D.A.; Bennett, D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61, 661-666. [CrossRef] [PubMed]
14. Frisardi, V.; Solfrizzi, V.; Seripa, D.; Capurso, C.; Santamato, A.; Sancarlo, D.; Vendemiale, G.; Pilotto, A.; Panza, F. Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer’s disease. Ageing Res. Rev. 2010, 9, 399-417. [CrossRef] [PubMed]
15. Daviglus, M.L.; Plassman, B.L.; Pirzada, A.; Bell, C.C.; Bowen, P.E.; Burke, J.R.; Connolly, E.S., Jr.; Dunbar-Jacob, J.M.; Granieri, E.C.; McGarry, K.; et al. Risk factors and preventive interventions for Alzheimer disease: State of the science. Arch. Neurol. 2011, 68, 1185-1190. [CrossRef] [PubMed]
16. Crane, P.K.; Walker, R.; Hubbard, R.A.; Li, G.; Nathan, D.M.; Zheng, H.; Haneuse, S.; Craft, S.; Montine, T.J.; Kahn, S.E.; et al. Glucose levels and risk of dementia. N. Engl. J. Med. 2013, 369, 540-548. [CrossRef] [PubMed]
17. Ott, A.; Stolk, R.P.; van Harskamp, F.; Pols, H.A.P.; Hofman, A.; Breteler, M.M.B. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53, 1937-1942. [CrossRef] [PubMed]
18. Convit, A.; Wolf, O.T.; Tarshish, C.; de Leon, M.J. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. PNAS 2003, 100, 2019-2022. [CrossRef] [PubMed]
19. Steen, E.; Terry, B.M.; Rivera, E.J.; Cannon, J.L.; Neely, T.R.; Tavares, R.; Xu, X.J.; Wands, J.R.; de la Monte, S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—Is this type 3 diabetes? J. Alzheimers Dis. 2005, 7, 63-80. [PubMed]
20. Rönnemaa, E.; Zethelius, B.; Sundelöf, J.; Sundström, J.; Degerman-Gunnarsson, M.; Berne, C.; Lannfelt, L.; Kilander, L. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008, 71, 1065-1071. [CrossRef] [PubMed]
21. Panza, F.; Frisardi, V.; Capurso, C.; Imbimbo, B.P.; Vendemiale, G.; Santamato, A.; D’Onofrio, G.; Seripa, D.; Sancarlo, D.; Pilotto, A.; et al. Metabolic syndrome and cognitive impairment: Current epidemiology and possible underlying mechanisms. J. Alzheimers Dis. 2010, 21, 691-724. [PubMed]
22. Ohara, T.; Doi, Y.; Ninomiya, T.; Hirakawa, Y.; Hata, J.; Iwaki, T.; Kanba, S.; Kiyohara, Y. Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology 2011, 77, 1126-1134. [CrossRef] [PubMed]
23. De Felice, F.G.; Ferreira, S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63, 2262-2272. [CrossRef] [PubMed]
24. Lacroix, M.C.; Badonnel, K.; Meunier, N.; Tan, F.; Schlegel-Le Poupon, C.; Durieux, D.; Monnerie, R.; Baly, C.; Congar, P.; Salesse, R. et al. Expression of insulin system in the olfactory epithelium: First approaches to its role and regulation. J. Neuroendocrinol. 2008, 20, 1176-1190. [CrossRef] [PubMed]
25. Kuwabara, T.; Kagalwala, M.N.; Onuma, Y.; Ito, Y.; Warashina, M.; Terashima, K.; Sanosaka, T.; Nakashima, K.; Gage, F.H.; Asashima, M. Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol. Med. 2011, 3, 742-754. [CrossRef] [PubMed]
26. Bingham, E.M.; Hopkins, D.; Smith, D.; Pernet, A.; Hallett, W.; Reed, L.; Marsden, P.K.; Amiel, S.A. The role of insulin in human brain glucose metabolism: An 18 fluoro-deoxyglucose positron emission tomography study. Diabetes 2002, 51, 3384-3390. [CrossRef] [PubMed]
27. Zhao, W.Q.; Chen, H.; Quon, M.J.; Alkon, D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 2004, 490, 71-81. [CrossRef] [PubMed]
28. Huang, T.J.; Verkhratsky, A.; Fernyhough, P. Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons. Mol. Cell. Neurosci. 2005, 28, 42-54. [CrossRef] [PubMed]
29. Duarte, A.I.; Proença, T.; Oliveira, C.R.; Santos, M.S.; Rego, A.C. Insulin restores metabolic function in cultured cortical neurons subjected to oxidative stress. Diabetes 2006, 55, 2863-2870. [CrossRef] [PubMed]
30. Salkovic-Petrisic, M.; Tribl, F.; Schmidt, M.; Hoyer, S.; Riederer, P. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J. Neurochem. 2006, 96, 1005-1015. [CrossRef] [PubMed]
31. Baker, L.D.; Cross, D.J.; Minoshima, S.; Belongia, D.; Watson, G.S.; Craft, S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2010, 68, 51-57. [CrossRef] [PubMed]
32. Ho, L.; Qin, W.; Pompl, P.N.; Xiang, Z.; Wang, J.; Zhao, Z.; Peng, Y.; Cambareri, G.; Rocher, A.; Mobbs, C.V. et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 2004, 18, 902-904. [CrossRef] [PubMed]
33. Li, Y.; Duffy, K.B.; Ottinger, M.A.; Ray, B.; Bailey, J.A.; Holloway, H.W.; Tweedie, D.; Perry, T.; Mattson, M.P.; Kapogiannis, D. et al. GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J. Alzheimers Dis. 2010, 19, 1205-1219. [PubMed]
34. Plaschke, K.; Kopitz, J.; Siegelin, M.; Schliebs, R.; Salkovic-Petrisic, M.; Riederer, P.; Hoyer, S. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AβPP-overexpressing mice. J. Alzheimers Dis. 2010, 19, 691-704. [PubMed]
35. Takeda, S.; Sato, N.; Uchio-Yamada, K.; Sawada, K.; Kunieda, T.; Takeuchi, D.; Kurinami, H.; Shinohara, M.; Rakugi, H.; Morishita, R. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβdeposition in an Alzheimer mouse model with diabetes. PNAS 2010, 107, 7036-7041. [CrossRef] [PubMed]
36. Bitela, C.L.; Kasinathanb, C.; Kaswalab, R.H.; Klein, W.L.; Frederiksea, P.H. Amyloid- β and Tau Pathology of Alzheimer’s Disease Induced by Diabetes in a Rabbit Animal Model. J. Alzheimers Dis. 2012, 32, 291-305.
37. Currais, A.; Prior, M.; Lo, D.; Jolivalt, C.; Schubert, D.; Maher, P. Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice. Aging Cell 2012, 11, 1017-1026. [CrossRef] [PubMed]
38. Maesako, M.; Uemura, K.; Kubota, M.; Kuzuya, A.; Sasaki, K.; Asada, M.; Watanabe, K.; Hayashida, N.; Ihara, M.; Ito, H. et al. Environmental enrichment ameliorated high-fat diet-induced Aβ deposition and memory deficit in APP transgenic mice. Neurobiol. Aging 2012, 33, 1011.e11-1011.e23. [CrossRef] [PubMed]
39. Son, S.M.; Song, H.; Byun, J.; Park, K.S.; Jang, H.C.; Park, Y.J.; Mook-Jung, I. Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy 2012, 8, 1842-1844. [CrossRef] [PubMed]
40. Yamamoto, N.; Matsubara, T.; Sobue, K.; Tanida, M.; Kasahara, R.; Naruse, K.; Taniura, H.; Sato, T.; Suzuki, K. Brain insulin resistance accelerates Aβ fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J. Neurochem. 2012, 121, 619-628. [CrossRef] [PubMed]
41. Chen, Y.; Liang, Z.; Blanchard, J.; Dai, C.L.; Sun, S.; Lee, M.H.; Grundke-Iqbal, I.; Iqbal, K.; Liu, F.; Gong, C.X. A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: Similarities to and differences from the transgenic model (3xTg-AD mouse). Mol. Neurobiol. 2013, 47, 711-725. [CrossRef] [PubMed]
42. Yang, Y.; Wu, Y.; Zhang, S.; Song, W. High glucose promotes Aβ production by inhibiting APP degradation. PLoS ONE 2013, 8, e69824. [CrossRef] [PubMed]
43. Mehlaa, J.; Chauhanc, B.C.; Chauhana, N.B. Experimental Induction of Type 2 Diabetes in Aging-Accelerated Mice Triggered Alzheimer-Like Pathology and Memory Deficits. J. Alzheimers Dis. 2014, 39, 145-162.
44. Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E.A.; Denis, P.; Teplow, D.B.; Ross, S.; Amarante, P.; Loeloffs, R. et al. β -Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735-741. [CrossRef] [PubMed]
45. Sisodia, S.S.; St George-Hyslop, P.H. Gamma-Secretase, Notch, Aβ and Alzheimer’s disease: Where do the presenilins fit in? Nat. Rev. Neurosci. 2002, 3, 281-290. [CrossRef] [PubMed]
46. Li, Y.M.; Lai, M.T.; Xu, M.; Huang, Q.; DiMuzio-Mower, J.; Sardana, M.K.; Shi, X.P.; Yin, K.C.; Shafer, J.A.; Gardell, S.J. Presenilin 1 is linked with-secretase activity in the detergent solubilized state. PNAS 2000, 97, 6138-6143. [CrossRef] [PubMed]
47. Yu, G.; Nishimura, M.; Arakawa, S.; Levitan, D.; Zhang, L.; Tandon, A.; Song, Y.Q.; Rogaeva, E.; Chen, F.; Kawarai, T. et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing. Nature 2000, 407, 48-54. [PubMed]
48. Francis, R.; McGrath, G.; Zhang, J.; Ruddy, D.A.; Sym, M.; Apfeld, J.; Nicoll, M.; Maxwell, M.; Hai, B.; Ellis, M.C. et al. Aph-1 and pen-2 are required for Notch pathway signaling,-secretase cleavage of βAPP, and presenilin protein accumulation. Dev. Cell 2000, 3, 85-97. [CrossRef]
49. Goutte, C.; Tsunozaki, M.; Hale, V.A.; Priess, J.R. APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. PNAS 2002, 99, 775-779. [CrossRef] [PubMed]
50. Sherrington, R.; Rogaev, E.I.; Liang, Y.; Rogaeva, E.A.; Levesque, G.; Ikeda, M.; Chi, H.; Lin, C.; Li, G.; Holman, K. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995, 375, 754-760. [CrossRef] [PubMed]
51. Hardy, J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 1997, 20, 154-159. [CrossRef]
52. Borchelt, D.R.; Thinakaran, G.; Eckman, C.B.; Lee, M.K.; Davenport, F.; Ratovitsky, T.; Prada, C.M.; Kim, G.; Seekins, S.; Yager, D. et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17, 1005-1013. [CrossRef]
53. Duff, K.; Eckman, C.B.; Zehr, C.; Yu, X.; Prada, C.M.; Perez-tur, J.; Hutton, M.; Buee, L.; Harigaya, Y.; Yager, D. et al. Increased amyloid- β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383, 710-713. [CrossRef] [PubMed]
54. Scheuner, D.; Eckman, C.B.; Jensen, M.; Song, X.; Citron, M.; Suzuki, N.; Bird, T.D.; Hardy, J.; Hutton, M.; Kukull, W. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 1996, 2, 864-870. [CrossRef] [PubMed]
55. Decker, H.; Lo, K.Y.; Unger, S.M.; Ferreira, S.T.; Silverman, M.A. Amyloid- β peptide oligomers disrupt axonal transport through an NMDA receptordependent mechanism that is mediated by glycogen synthase kinase 3β in primary cultured hippocampal neurons. J. Neurosci. 2010, 30, 9166-9171. [CrossRef] [PubMed]
56. Vossel, K.A.; Zhang, K.; Brodbeck, J.; Daub, A.C.; Sharma, P.; Finkbeiner, S.; Cui, B.; Mucke, L. Tau reduction prevents Aβ-induced defects in axonal transport. Science 2010, 330, 198. [CrossRef] [PubMed]
57. Tang, Y.; Scott, D.A.; Das, U.; Edland, S.D.; Radomski, K.; Koo, E.H.; Roy, S. Early and selective impairments in axonal transport kinetics of synaptic cargoes induced by soluble amyloid β-protein oligomers. Traffic 2012, 13, 681-693. [CrossRef] [PubMed]
58. Li, Z.; Okamoto, K.; Hayashi, Y.; Sheng, M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119, 873-887. [CrossRef] [PubMed]
59. Sheng, Z.H.; Cai, Q. Mitochondrial transport in neurons: Impact on synaptic homeostasis and neurodegeneration. Nat. Rev. Neurosci. 2012, 13, 77-93. [CrossRef] [PubMed]
60. Sheng, Z.H. Mitochondrial trafficking and anchoring in neurons: New insight and implications. J. Cell Biol. 2014, 204, 1087-1098. [CrossRef] [PubMed]
61. Luine, V.; Frankfurt, M. Interactions between estradiol, BDNF and dendritic spines in promoting memory. Neuroscience 2012, 239, 34-45. [CrossRef] [PubMed]
62. Kellner, Y.; Gödecke, N.; Dierkes, T.; Thieme, N.; Zagrebelsky, M.; Korte, M. The BDNF effects on dendritic spines of mature hippocampal neurons depend on neuronal activity. Front. Synaptic Neurosci. 2014, 6, 5. [CrossRef] [PubMed]
63. Scharfman, H.E.; Chao, M.V. The entorhinal cortex and neurotrophin signaling in Alzheimer’s disease and other disorders. Cogn. Neurosci. 2013, 4, 123-135. [CrossRef] [PubMed]
64. Khatri, N.; Man, H.Y. Synaptic activity and bioenergy homeostasis: Implications in brain trauma and neurodegenerative diseases. Front. Neurol. 2013, 4, 199. [CrossRef] [PubMed]
65. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L. et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. PNAS 1998, 95, 6448-6453. [CrossRef] [PubMed]
66. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416, 535-539. [CrossRef] [PubMed]
67. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, I.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A. et al. Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 2008, 14, 837-842. [CrossRef] [PubMed]
68. Li, S.; Hong, S.; Shepardson, N.E.; Walsh, D.M.; Shankar, G.M.; Selkoe, D. Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62, 788-801. [CrossRef] [PubMed]
69. Lacor, P.N.; Buniel, M.C.; Furlow, P.W.; Clemente, A.S.; Velasco, P.T.; Wood, M.; Viola, K.L.; Klein, W.L. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J. Neurosci. 2007, 27, 796-807. [CrossRef] [PubMed]
70. Shankar, G.M.; Bloodgood, B.L.; Townsend, M.; Walsh, D.M.; Selkoe, D.J.; Sabatini, B.L. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27, 2866-2875. [CrossRef] [PubMed]
71. Jolivalt, C.G.; Hurford, R.; Lee, C.A.; Dumaop, W.; Rockenstein, E.; Masliah, E. Type 1 diabetes exaggerates features of Alzheimer’s disease in APP transgenic mice. Exp. Neurol. 2010, 223, 22-31. [CrossRef] [PubMed]
72. Devi, L.; Alldred, M.J.; Ginsberg, S.D.; Ohno, M. Mechanisms underlying insulin deficiency-induced acceleration of β-amyloidosis in a mouse model of Alzheimer’s disease. PLoS ONE 2012, 7, e32792. [CrossRef] [PubMed]
73. Liu, Y.; Liu, H.; Yang, J.; Liu, X.; Lu, S.; Wen, T.; Xie, L.; Wang, G. Increased amyloid β-peptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neuroscience 2008, 153, 796-802. [CrossRef] [PubMed]
74. Wang, J.Q.; Yin, J.; Song, Y.F.; Zhang, L.; Ren, Y.X.; Wang, D.G.; Gao, L.P.; Jing, Y.H. Brain aging and AD-like pathology in streptozotocin-induced diabetic rats. J. Diabetes Res. 2014, 2014, 796840. [CrossRef] [PubMed]
75. Plaschke, K.; Hoyer, S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int. J. Dev. Neurosci. 1993, 11, 477-483. [CrossRef]
76. Duelli, R.; Schröck, H.; Kuschinsky, W.; Hoyer, S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int. J. Dev. Neurosci. 1994, 12, 737-743. [CrossRef]
77. Hoyer, S.; Müller, D.; Plaschke, K. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J. Neural Transm. Suppl. 1994, 44, 259-268. [PubMed]
78. Lannert, H.; Hoyer, S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 1998, 112, 1199-1208. [CrossRef] [PubMed]
79. Lin, F.; Jia, J.; Qin, W. Enhancement of β-amyloid oligomer accumulation after intracerebroventricular injection of streptozotocin, which involves central insulin signaling in a transgenic mouse model. Neuroreport 2014, 25, 1289-1295. [CrossRef] [PubMed]
80. Iwata, N.; Tsubuki, S.; Takaki, Y.; Watanabe, K.; Sekiguchi, M.; Hosoki, E.; Kawashima-Morishima, M.; Lee, H.J.; Hama, E.; Sekine-Aizawa, Y. et al. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat. Med. 2000, 6, 143-150. [CrossRef] [PubMed]
81. Eckman, E.A.; Reed, D.K.; Eckman, C.B. Degradation of the Alzheimer’s amyloid β peptide by endothelin-converting enzyme. J. Biol. Chem. 2001, 276, 24540-24548. [CrossRef] [PubMed]
82. Qiu, W.Q.; Walsh, D.M.; Ye, Z.; Vekrellis, K.; Zhang, J.; Podlisny, M.B.; Rosner, M.R.; Safavi, A.; Hersh, L.B.; Selkoe, D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 1998, 273, 32730-32738. [CrossRef] [PubMed]
83. Liu, Y.; Liu, L.; Lu, S.; Wang, D.; Liu, X.; Xie, L.; Wang, G. Impaired amyloid β-degrading enzymes in brain of streptozotocin-induced diabetic rats. J. Endocrinol. Investig. 2011, 34, 26-31. [CrossRef]
84. Vandal, M.; White, P.J.; Tremblay, C.; St-Amour, I.; Chevrier, G.; Emond, V.; Lefrançois, D.; Virgili, J.; Planel, E.; Giguere, Y. et al. Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes 2014, 63, 4291-4301. [CrossRef] [PubMed]
85. Mehla, J.; Chauhan, B.C.; Chauhan, N.B. Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. J. Alzheimers Dis. 2014, 39, 145-162. [PubMed]
86. Cao, D.; Lu, H.; Lewis, T.L.; Li, L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2007, 282, 36275-36282. [CrossRef] [PubMed]
87. Li, Z.G.; Zhang, W.; Sima, A.A. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56, 1817-1824. [CrossRef] [PubMed]
88. Nagai, N.; Ito, Y.; Tanino, T. Effect of high glucose levels on amyloid β production in retinas of spontaneous diabetes mellitus Otsuka Long-Evans Tokushima fatty rats. Biol. Pharm. Bull. 2015, 38, 601-610. [CrossRef] [PubMed]
89. Cataldo, A.M.; Nixon, R.A. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. PNAS 1990, 87, 3861-3865. [CrossRef] [PubMed]
90. Cataldo, A.M.; Barnett, J.L.; Pieroni, C.; Nixon, R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer’s disease: Neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J. Neurosci. 1997, 17, 6142-6151. [PubMed]
91. Cataldo, A.M.; Petanceska, S.; Terio, N.B.; Peterhoff, C.M.; Durham, R.; Mercken, M.; Metha, P.D.; Buxbaum, J.; Haroutunian, V.; Nixon, R.A. Aβ localization in abnormal endosomes: Association with earliest Aβ elevations in AD a syndrome. Neurobiol. Aging 2004, 25, 1263-1272. [CrossRef] [PubMed]
92. Nixon, R.A. Endosome function and dysfunction in Alzheimer’s disease and other neurodegenerative diseases. Neurobiol. Aging 2005, 26, 373-382. [CrossRef] [PubMed]
93. Nixon, R.A. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 2007, 120, 4081-4091. [CrossRef] [PubMed]
94. Kimura, N.; Inoue, M.; Okabayashi, S.; Ono, F.; Negishi, T. Dynein dysfunction induces endocytic pathology accompanied by an increase in Rab GTPases: A potential mechanism underlying age-dependent endocytic dysfunction. J. Biol. Chem. 2009, 284, 31291-31302. [CrossRef] [PubMed]
95. Kimura, N.; Okabayashi, S.; Ono, F. Dynein dysfunction disrupts intracellular vesicle trafficking bidirectionally and perturbs synaptic vesicle docking via endocytic disturbances a potential mechanism underlying age-dependent impairment of cognitive function. Am. J. Pathol. 2012, 180, 550-561. [CrossRef] [PubMed]
96. Grbovic, O.M.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Dinakar, R.; Summers-Terio, N.B.; Ceresa, B.P.; Nixon, R.A.; Cataldo, A.M. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular β-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Aβ production. J. Biol. Chem. 2003, 278, 31261-31268. [CrossRef] [PubMed]
97. Koh, Y.H.; von Arnim, C.A.; Hyman, B.T.; Tanzi, R.E.; Tesco, G. BACE is degraded via the lysosomal pathway. J. Biol. Chem. 2005, 280, 32499-32504. [CrossRef] [PubMed]
98. Lefort, R.; Pozueta, J.; Shelanski, M. Cross-linking of cell surface amyloid precursor protein leads to increased β-amyloid peptide production in hippocampal neurons: Implications for Alzheimer’s disease. J. Neurosci. 2012, 32, 10674-10685. [CrossRef] [PubMed]
99. Harold, D.; Abraham, R.; Hollingworth, P.; Sims, R.; Gerrish, A.; Hamshere, M.L.; Pahwa, J.S.; Moskvina, V.; Dowzell, K.; Williams, A. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet. 2009, 41, 1088-1093. [CrossRef] [PubMed]
100. Seshadri, S.; Fitzpatrick, A.L.; Ikram, M.A.; DeStefano, A.L.; Gudnason, V.; Boada, M.; Bis, J.C.; Smith, A.V.; Carassquillo, M.M.; Lambert, J.C. et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303, 1832-1840. [CrossRef] [PubMed]
101. Vardarajan, B.N.; Bruesegem, S.Y.; Harbour, M.E.; St George-Hyslop, P.; Seaman, M.N.; Farrer, L.A. Identification of Alzheimer disease associated variants in genes that regulate retromer function. Neurobiol. Aging 2012, 33, 2231. [CrossRef] [PubMed]
102. Talwar, P.; Silla, Y.; Grover, S.; Gupta, M.; Agarwal, R.; Kushwaha, S.; Kukreti, R. Genomic convergence and network analysis approach to identify candidate genes in Alzheimer’s disease. BMC Genom. 2014, 15, 199. [CrossRef] [PubMed]
103. Chouraki, V.; Seshadri, S. Genetics of Alzheimer’s disease. Adv. Genet. 2014, 87, 245-294. [PubMed]
104. Okabayashi, S.; Shimozawa, N.; Yasutomi, Y.; Yanagisawa, K.; Kimura, N. Diabetes mellitus accelerates Aβ pathology in brain accompanied by enhanced GAβ generation in nonhuman primates. PLoS ONE 2015, 10, e0117362. [CrossRef] [PubMed]
105. Lane, R.F.; Raines, S.M.; Steele, J.W.; Ehrlich, M.E.; Lah, J.A.; Small, S.A.; Tanzi, R.E.; Attie, A.D.; Gandy, S. Diabetes-associated SorCS1 regulates Alzheimer’s amyloid-β metabolism: Evidence for involvement of SorL1 and the retromer complex. J. Neurosci. 2010, 30, 13110-13115. [CrossRef] [PubMed]
106. Iqbal, K.; Alonso Adel, C.; Chen, S.; Chohan, M.O.; El-Akkad, E.; Gong, C.X.; Khatoon, S.; Li, B.; Liu, F.; Rahman, A. et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 2005, 1739, 198-210. [CrossRef] [PubMed]
107. Imahori, K.; Uchida, T. Physiology and pathology of tau protein kinases in relation to Alzheimer’s disease. J. Biochem. 1997, 121, 179-188. [PubMed]
108. Ishiguro, K.; Omori, A.; Takamatsu, M.; Sato, K.; Arioka, M.; Uchida, T.; Imahori, K. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett. 1992, 148, 202-206. [CrossRef]
109. Michel, G.; Mercken, M.; Murayama, M.; Noguchi, K.; Ishiguro, K.; Imahori, H.; Takashima, A. Characterization of tau phosphorylation in glycogen synthase kinase-3β and cyclin dependent kinase-5 activator (p23) transfected cells. Biochim. Biophys. Acta 1998, 1380, 177-182. [CrossRef]
110. Godeman, R.; Biernat, J.; Mandelkow, E.; Mandelkow, E.M. Phosphorylation of tau protein by recombinant GSK3β: Pronounced phosphorylation at select Ser/Thr-Pro motif but no phosphorylation at Ser267 in the repeat domain. FEBS Lett. 1999, 454, 157-164. [CrossRef]
111. Hanger, D.P.; Hughes, K.; Woodgett, J.R.; Brion, J.P.; Anderton, B.H. Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 1992, 147, 58-62. [CrossRef]
112. Ullrich, A.; Bell, J.R.; Chen, E.Y.; Herrera, R.; Petruzzelli, L.M.; Dull, T.J.; Gray, A.; Coussens, L.; Liao, Y.C.; Tsubokawa, M. et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985, 313, 756-761. [CrossRef] [PubMed]
113. Myers, M.G., Jr.; Sun, X.J.; White, M.F. The IRS-1 signaling system. Trends Biochem. Sci. 1994, 19, 289-293. [CrossRef]
114. O’Hare, T.; Pilch, P.F. Intrinsic kinase activity of the insulin receptor. Int. J. Biochem. 1990, 22, 315-324. [CrossRef]
115. Ghasemi, R.; Haeri, A.; Dargahi, L.; Mohamed, Z.; Ahmadiani, A. Insulin in the brain: Sources, localization and functions. Mol. Neurobiol. 2013, 47, 145-171. [CrossRef] [PubMed]
116. Adamo, M.L.; Shemer, J.; Roberts, C.T., Jr.; LeRoith, D. Insulin and insulin-like growth factor-I induced phosphorylation in neurally derived cells. Ann. N. Y. Acad. Sci. 1993, 692, 113-125. [CrossRef] [PubMed]
117. Abbott, M.A.; Wells, D.G.; Fallon, J.R. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J. Neurosci. 1999, 19, 7300-7308. [PubMed]
118. Werther, G.A.; Hogg, A.; Oldfield, B.J.; McKinley, M.J.; Figdor, R.; Allen, A.M.; Mendelsohn, F.A. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987, 121, 1562-1570. [CrossRef] [PubMed]
119. Dozza, B.; Smith, M.A.; Perry, G.; Tabaton, M.; Strocchi, P. Regulation of glycogen synthase kinase-3β by products of lipid peroxidation in human neuroblastoma cells. J. Neurochem. 2004, 89, 1224-1232. [CrossRef] [PubMed]
120. Ke, Y.D.; Delerue, F.; Gladbach, A.; Götz, J.; Ittner, L.M. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer’s disease. PLoS ONE 2009, 4, e7917. [CrossRef] [PubMed]
121. Gong, C.X.; Singh, T.J.; Grundke-Iqbal, I.; Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 1993, 61, 921-927. [CrossRef] [PubMed]
122. Gong, C.X.; Shaikh, S.; Wang, J.Z.; Zaidi, T.; Grundke-Iqbal, I.; Iqbal, K. Phosphatase activity toward abnormally phosphorylated tau: Decrease in Alzheimer disease brain. J. Neurochem. 1995, 65, 732-738. [CrossRef] [PubMed]
123. Vogelsberg-Ragaglia, V.; Schuck, T.; Trojanowski, J.Q.; Lee, V.M. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp. Neurol. 2001, 168, 402-412. [CrossRef] [PubMed]
124. Tanimukai, H.; Grundke-Iqbal, I.; Iqbal, K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease. Am. J. Pathol. 2005, 166, 1761-1771. [CrossRef]
125. Planel, E.; Tatebayashi, Y.; Miyasaka, T.; Liu, L.; Wang, L.; Herman, M.; Yu, W.H.; Luchsinger, J.A.; Wadzinski, B.; Duff, K.E. et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J. Neurosci. 2007, 27, 13635-13648. [CrossRef] [PubMed]
126. Clodfelder-Miller, B.J.; Zmijewska, A.A.; Johnson, G.V.; Jope, R.S. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 2006, 55, 3320-3325. [CrossRef] [PubMed]
127. Papon, M.A.; El Khoury, N.B.; Marcouiller, F.; Julien, C.; Morin, F.; Bretteville, A.; Petry, F.R.; Gaudreau, S.; Amrani, A.; Mathews, P.M. et al. Deregulation of protein phosphatase 2A and hyperphosphorylation of β protein following onset of diabetes in NOD mice. Diabetes 2013, 62, 609-617. [CrossRef] [PubMed]
128. Chen, Y.; Zhao, Y.; Dai, C.L.; Liang, Z.; Run, X.; Iqbal, K.; Liu, F.; Gong, C.X. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp. Neurol. 2014, 261, 610-619. [CrossRef] [PubMed]
129. Pedrós, I.; Petrov, D.; Allgaier, M.; Sureda, F.; Barroso, E.; Beas-Zarate, C.; Auladell, C.; Pallàs, M.; Vázquez-Carrera, M.; Casadesús, G. et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer’s disease. Biochim. Biophys. Acta 2014, 1842, 1556-1566. [CrossRef] [PubMed]
130. Craft, S.; Baker, L.D.; Montine, T.J.; Minoshima, S.; Watson, G.S.; Claxton, A.; Arbuckle, M.; Callaghan, M.; Tsai, E.; Plymate, S.R. et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch. Neurol. 2012, 69, 29-38. [CrossRef] [PubMed]
131. Claxton, A.; Baker, L.D.; Hanson, A.; Trittschuh, E.H.; Cholerton, B.; Morgan, A.; Callaghan, M.; Arbuckle, M.; Behl, C.; Craft, S. Longacting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or earlystage Alzheimer’s disease dementia. J. Alzheimers Dis. 2015, 44, 897-906. [PubMed]